Sponsor overview

Duke University

Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.

Back to report

Summary

Signal counts

Assets tracked: 4

Watchlist assets: 2

Registry stop assets: 2

Evidence links

Public sources

https://clinicaltrials.gov/study/NCT00612430 | https://clinicaltrials.gov/study/NCT01820754 | https://clinicaltrials.gov/study/NCT04863885 | https://clinicaltrials.gov/study/NCT05200143 | https://clinicaltrials.gov/study/NCT03307616 | https://clinicaltrials.gov/study/NCT01585194 | https://clinicaltrials.gov/study/NCT03340129 | https://clinicaltrials.gov/study/NCT00918385 | https://clinicaltrials.gov/study/NCT03856359

Assets

Linked programs

Bevacizumab and Etoposide: Low Signal (0/5)
Ipilimumab: Registry Stop Signal (4/5)
Nilutamide: Registry Stop Signal (4/5)
Rifaximin 550 milligrams (MG): Low Signal (0/5)